The following statement from the announcement for the P2 study...

The following statement from the announcement for the P2 study is very telling that Redhill Biopharma may not achieve the primary endpoint for their COVID study, since they found no difference in the number of patients requiring mechanical ventilation in their P2 study. The next critical point will be their third interim DMSB analysis, and if they fail this then NOX gains back full advantage in the SP1 inhibition space.

However, I don't think NOXCOVID will be of much significance to the company other than as an information gathering exercise. This is mostly because MK-7110 (formerly SACCOVID) is likely to be approved shortly for COVID-19 and it treats precisely what Veyonda expected to treat. MK-7110 also recently received money from operation warp speed to scale up production, and along with vaccines, this space is likely to become crowded very quickly.

I like the potential for Veyonda to treat cancer and have bought in for that very reason.

https://ir.redhillbio.com/news-releases/news-release-details/redhill-biopharma-announces-positive-top-line-safety-and

• Top-line results from the study found opaganib to be safe, with no material safety differences between the opaganib and placebo treatment arms. Overall, fewer patients suffered from serious adverse events (SAEs) in the opaganib treatment arm than in the placebo arm. In this small sample size, there were few events of intubation or fatality and these were balanced between the two arms.

https://www.clinicaltrials.gov/ct2/show/NCT04467840?term=opaganib&draw=2&rank=2

Primary Outcome Measures :

1. Intubation and mechanical ventilation [ Time Frame: 14 days ]
   To compare the proportion of patients requiring intubation and mechanical ventilation by Day 14 between subjects taking opaganib and those on placebo.

GLTAH